Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
yifei sanjie wan
- Development stage
- Unknown
- Lead developer
- Guangzhou University of Chinese Medicine
- Administration
- Oral
01
Overview
Yifei Sanjie Wan (YFSJ) is a Traditional Chinese Medicine (TCM) formula primarily utilized in China for the treatment of non-small cell lung cancer (NSCLC). It is frequently employed as an adjunctive therapy to enhance the efficacy of chemotherapy (such as platinum-based doublets) and targeted agents like gefitinib or anlotinib. Mechanistically, YFSJ has been shown to inhibit the epithelial-mesenchymal transition (EMT) by modulating the EGFR/p-p38 MAPK/GSK3β signaling axis, thereby reducing tumor cell migration, invasion, and drug resistance. Additionally, it is being investigated for its potential to alleviate chemotherapy-induced cancer-related fatigue in lung cancer patients.
- Other names
- Yifei Sanjie RecipeYifei Sanjie PillYFSJ益肺散结丸
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)BNIP3 (BCL2/adenovirus E1B 19 kDa protein-interacting protein 3)EGFR (Epidermal growth factor receptor)HIF1A (Hypoxia-inducible factor 1-alpha)FXR (Farnesoid x-activated receptor)PIK3CA (Phosphoinositide 3-kinase alpha)STAT3 (Signal Transducer and Activator of Transcription 3)USP7GSK3 (Glycogen synthase kinase 3 beta)MAPK14 (p38 mitogen-activated protein kinase alpha)
Beyond the preview
Go deeper on yifei sanjie wan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on yifei sanjie wan.